Welcome to our dedicated page for Aptargroup SEC filings (Ticker: ATR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AptarGroup, Inc.'s SEC filings document operating results, governance matters and capital-structure activity for a NYSE-listed maker of drug delivery and consumer-product dispensing technologies. Form 8-K reports furnish quarterly and annual results, segment commentary for Pharma, Beauty and Closures, shareholder returns and material events tied to the company's operations.
The filing record also includes proxy materials and annual meeting vote results covering director elections, advisory compensation matters and stockholder voting items. Capital disclosures include common stock registered under the Exchange Act, shelf-registration activity and completed debt financing, including the 4.750% Senior Notes due 2031 issued under an indenture.
AptarGroup, Inc. reported first-quarter 2026 net sales of $982.9 million, up 11% from $887.3 million a year earlier. Foreign exchange and acquisitions drove most of the increase, leaving core sales roughly flat. Net income attributable to AptarGroup was $72.7 million, down from $78.8 million, and diluted EPS declined to $1.12 from $1.17 as margins compressed.
Pharma sales rose to $438.6 million but core sales dipped 1% on lower emergency medicine volumes, while Beauty and Closures delivered modest core growth. Operating margin decreased to 10.9% from 12.8%. Cash flow from operations strengthened to $118.7 million, supporting $65.4 million of capital spending and $100.0 million of share repurchases under a new $600 million authorization.
AptarGroup reported mixed first quarter 2026 results, with solid top-line growth but softer profit metrics. Net sales rose 11% to $982.9 million, while reported net income declined 8% to $72.8 million and diluted earnings per share slipped to $1.12 from $1.17.
On an adjusted basis, earnings per share were $1.19, down from $1.30 a year earlier at comparable exchange rates, and adjusted EBITDA margin narrowed to 19.2% from 20.7% as mix and operational issues weighed on profitability. Pharma and Closures saw core sales pressure from emergency medicine destocking, lower resin pricing and temporary plant disruptions, while Beauty delivered 3% core growth.
The company returned $131 million to shareholders through dividends and share repurchases in the quarter, including buying back 707,000 shares for $100 million, and the board approved a quarterly dividend of $0.48 per share. For the second quarter of 2026, AptarGroup expects adjusted earnings per share between $1.32 and $1.40, assuming an effective tax rate of 22.5% to 24.5% and a 1.18 EUR/USD exchange rate. The company also announced that Gael Touya will become CEO effective September 1, 2026.
AptarGroup Inc reports an institutional beneficial ownership filing showing Vanguard Capital Management beneficially owns 3,376,965 shares of Common Stock, representing 5.29% of the class. The filing states Vanguard has sole dispositive power over 3,376,965 shares and sole voting power over 491,668 shares. The disclosure explains these holdings reflect securities managed across Vanguard affiliates and funds.
AptarGroup Inc: Vanguard Portfolio Management reported beneficial ownership of 3,775,690 shares of AptarGroup common stock, representing 5.92% of the class. The filing lists sole voting power for 7,918 shares and sole dispositive power for 3,775,690 shares.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 04/28/2026.
AptarGroup, Inc. has released its 2026 proxy statement outlining the May 6, 2026 virtual annual meeting, director elections, executive pay, and key governance practices. Stockholders will vote on four director nominees for terms expiring in 2029, an advisory say-on-pay resolution, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.
The proxy describes a planned leadership transition in which Gael Touya becomes President and Chief Executive Officer on September 1, 2026, with current CEO Stephan B. Tanda moving to a strategic advisor role and remaining on the Board through December 31, 2026. It highlights 2025 record reported sales of $3.8 billion, annual net income of $393 million, diluted earnings per share of $5.89, and the 32nd consecutive year of increased aggregate annual dividends, alongside extensive sustainability, human capital, and board independence disclosures.
AptarGroup Inc — Amendment No. 15 to a Schedule 13G/A filed by The Vanguard Group reports 0 shares beneficially owned, representing 0% of AptarGroup common stock.
The filing explains an internal realignment of Vanguard on January 12, 2026 pursuant to SEC Release No. 34-39538, after which certain Vanguard subsidiaries report holdings separately and Vanguard "no longer has, or is deemed to have, beneficial ownership" of securities held by those subsidiaries.
APTARGROUP, INC. Segment President Hedi Tlili received a grant of 10,803 shares of Common Stock as a stock award with a reported price of $0.00 per share. Following this compensation-related acquisition, Tlili directly holds 21,323 shares of AptarGroup common stock.
Kanu Vanessa reported acquisition or exercise transactions in this Form 4 filing.
APTARGROUP, INC. executive vice president and CFO Vanessa Kanu received a grant of 10,960 shares of common stock as compensation. This award was recorded at no purchase price and increased her directly held stake to 24,646 shares, aligning her incentives more closely with shareholders.
APTARGROUP, INC. President and CEO Stephan B. Tanda received new equity awards as part of his compensation. He was granted a stock option for 53,691 shares of common stock at an exercise price of $123.97 per share, expiring on March 19, 2036. According to a footnote, this option vests in three equal installments starting on the first anniversary of the grant date.
He was also granted 13,796 shares of common stock, increasing his direct common stock holdings to 214,782 shares. In addition, 3,138 shares are held indirectly through a 401(k) trust. These are awards from the company, not open‑market purchases or sales.